A Beijing-educated former official at the US federal drug regulator has been appointed to lead Hong Kong’s new medical products body, tasked with accelerating the clinical use of medicines and medical devices as part of a regulatory overhaul. Li Zili, who previously worked at the US Food and Drug Administration (FDA), would take up the post of controller for medical products regulation under the Department of Health on a three-year term beginning October 20, the government said on Monday. He...